top of page

Search Results

Results found for "Brigitte Kieffer"

  • Structures of β 1-adrenergic receptor in complex with Gs and ligands of different efficacies

    August 2022 "G-protein-coupled receptors (GPCRs) receive signals from ligands with different efficacies , and transduce to heterotrimeric G-proteins to generate different degrees of physiological responses Previous studies revealed how ligands with different efficacies activate GPCRs. Analyses reveal similar overall complex architecture, with local conformational differences. ligands, with residue-specific functional differences.

  • Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of ...

    Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine Interestingly, there were also significant differences in receptor degradation, with S339fs5 having a

  • Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice

    However, the pharmacokinetic properties of DOI differed among sexes - brain and plasma concentrations Together, these results suggest strain-dependent and sex-related differences in the behavioral and pharmacokinetic

  • Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    complete the studies, quantitative live cell microscopy assay relies on cell segmentation from the bright-field Displacement of CELT-419 by different concentrations of Butaclamol  (A)  and PL-384  (B)  at different No substantial differences were found between them and the reporter. Figure 4.     Fluorescence and bright-field images of total (left panels) and non-specific binding (central panels) The contrast of fluorescence and bright-field images was enhanced for presentation purposes only, the

  • Regulation of rod photoreceptor function by farnesylated G-protein γ-subunits

    Bright illumination triggered Gαt1 translocation from the rod outer to inner segments in all three transgenic

  • Adhesion GPCR Consortium Newsletter - May 2024

    The meat on a rotating spit with its bright red/orange chili-based marinade (spicy but not hot) catches PMID: 38608683 The activation profile of different G proteins by ADGRL3 is shown using a collection of

  • Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!

    Ready for your GPCR quest, so bold and bright? Join us now, and let's explore with all our might!

  • Is Your Agonist Really “Working”—Or Are You Just Seeing What Your System Allows?

    Through powerful analogies (think batteries and balance scales), Terry reveals why different tissues—and even different assays—can paint totally different pictures of the same  compound.

  • 📰 GPCR Weekly News, February 19 to 25, 2024

    Fragment-Based Design, Synthesis, and Characterization of Aminoisoindole-Derived Furin Inhibitors A Bright

  • Breaking the Myth of High and Low Affinity Sites

    Every day spent misunderstanding the meaning of apparent affinity differences can slow your project’s At first glance, when a ligand appears to bind at two different affinities in the same system, it seems But are these differences really pointing to two physical sites?   Kenakin challenges this assumption and shows that what you’re seeing may reflect something entirely different

  • Why Intracellular Drugs May Hold the Key to GPCR Therapeutics

    Once a ligand crosses into this intracellular space, it behaves differently, often much more favorably These aren’t small differences. They’re the reason two equipotent drugs may perform very differently in vivo. Same Affinity, Different Outcomes: Why Residence Time Matters More Two ligands. Intracellular access transforms the kinetic profile of your drug, which may be the difference between

  • Reflections on My PhD Journey: Lessons Learned

    My experience has been no different, filled with valuable lessons that I hope will inspire and guide These rotations gave me the opportunity to explore the culture of different labs, understand ongoing What ultimately made the difference was my PhD supervisor’s initiative to reach out. Different supervisors offer different styles of mentorship, but it’s crucial to find one who genuinely

  • Chemokine receptor-targeted drug discovery: progress and challenges

    Different reviews have extensively described the success and failure in drug discovery on chemokine receptors At a molecular level, different ligands bind to the same receptor and vice-versa (Marcuzzi et al. 2018 In the chemokine-receptor system, different chemokines are able to activate different pathways, which Further difficulties arise from the existence of cross-reactivity with other GPCRs and differences in Overall, the future potential lies in using different therapeutic modalities to modulate the stromal

  • Profiling Immune Cell and Platelet Transcriptomes

    in transcriptomic profiling have provided new insights into the expression patterns of GPCRs across different Additionally, the study identified unique expression patterns of GPCRs in different immune cell types highlighting the robustness of the assay and the potential for cross-validation of GPCR expression across different

  • Building Backwards: Why Top-Down Models Could Revolutionize Pain Research

    Watch Episode 170 Thinking Differently Pain research has long followed a familiar route: from molecule He also integrates concepts like sex differences , epigenetic inheritance , and neuroimmune crosstalk

  • Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes

    Biased agonism is a phenomenon where different ligands acting on the same receptor trigger distinct signaling However, GLP-1R can also engage other G proteins, such as Gi/o and Gq/11, leading to different downstream Biased agonism at the GLP-1R has been extensively studied, revealing that different ligands can stabilize These differences in signaling profiles can have significant physiological implications. Cryo-electron microscopy (cryo-EM) structures of GLP-1R bound to different agonists have provided further

  • Molecular basis for ligand modulation of the cannabinoid CB 1 receptor

    New high-resolution structures of CB1 receptor in different functional states have significantly improved These advances have paved the way for development of novel ligands for different therapeutic applications In this review, we describe the structural determinants for modulation of CB1 receptors by different types of ligands, as well as the differences between CB1 and its homologous, the CB2 receptor.

  • AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof

    AlphaFold-predicted models revealed distinct ligand-binding site shapes, enabling the prioritization of different static structures was groundbreaking, however, GPCRs are highly dynamic proteins and continuously adopt different ligands and the cellular environment which are crucial for understanding how drugs can selectively target different

  • β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the...

    when coupling to the same GPCR in living cells "β-arrestins mediate regulatory processes for over 800 different However, whether β-arrestin1 and 2 respond differently for binding to the same GPCR is still unknown. that the two isoforms prefer to associate with the active parathyroid hormone 1 receptor (PTH1R) in different Here, we show differences between conformational changes that are induced by P-R* or R* receptor states

  • Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology

    Terry Kenakin reframes one of pharmacology’s most foundational ideas: the difference between competitive This lecture helps you not only understand these differences, but also know when and why they matter. This is the kind of insight that makes the difference between a dead-end program and a well-informed

  • GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery

    This lecture is a roadmap for understanding why two drugs with similar affinity may behave completely differently Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most What If the Same Site Behaves Differently Depending on the Ligand?

  • TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi

    What is the molecular basis that determines that GPCRs bind selectively or promiscuously to different Prior to this report we did not know how different serotonin receptor subtypes which share high sequence homology, coupled to different families of G proteins, so the comparison and structural analysis of The structural differences found between the receptor-Gs and receptor-Gi complexes evidenced that 5-HT4 These differences are mainly attributed to the characteristic Ras domain distance between Gs and Gi.

  • Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)

    It has been proven that when different ligands bind to the receptors the effects are different depending Raïch I et al. , Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinolderivatives

  • Radioligands vs. Fluorescent Ligands: Binding Assays

    Fluorescent Probes: Differences in Binding Assays Fluorescent ligands are a type of fluorescent probes ligands can be used at a broader range of concentration without losing accuracy, as well as detect different Ease of handling is the other key difference, because fluorescent compounds do not require regulatory

  • VAMP2: a crucial player in the delivery of MOR to the synapse

    The t-SNARE complex is composed of two different proteins: syntaxin and SNAP-25; syntaxin is found on However, the selectivity of SNARE complex proteins to regulate the release of different types of GPCRs its bi-leucine sequence (which is considered a key element in its recycling), which can interact with different fusion proteins and also this different molecular codes will be modulated by different opioids, either endogenous or exogenous, promoving a differential organization of MOR receptors in vesicles with different

  • Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...

    August 2022 "G-protein-coupled receptors (GPCR) are present at the cell surface in different conformational We used TIRF microscopy and a statistical method to track and classify the motion of different receptor These forms were stabilized differently by distinct ligands.

  • Comparative study of neuropeptide signaling systems in Hemiptera

    signaling system, there is still a great deal of variety in neuropeptides and their receptors among different Neuropeptides and their receptors have been documented in many hemipteran insects, but the differences Additionally, we discovered that the neuropeptide signaling systems of Sternorrhyncha were very different

  • The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor

    2022 "Background: Activation of signaling effectors by G-protein coupled receptors (GPCRs) depends on different indicated that transmembrane helix 7 (TMH7) and the highly conserved NPXXY motif can be subject to different

  • Ever Wondered How Drugs Are Discovered?

    You’ll explore: What makes a “discovery team” tick (and why teamwork is non-negotiable) The difference

  • Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling

    no generalizable GPCR conformations conducive to binding a particular type of partner; (ii) subtle differences receptor-transducer structures determine partner preference; or (iii) the dynamics of GPCR binding to different

bottom of page